Deals Shaping The Medical Industry, June 2016
Executive Summary
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2016.
You may also be interested in...
ASCO 2023 – Bicara Eyes Head And Neck Niche
Impressive data in HPV-negative disease, potentially beating Keytruda, has the private group making pivotal plans.
ADAURA Survival Boost For AZ’s Tagrisso
Impressive overall survival data from the Phase III ADAURA trial should boost both EGFR testing in non-small cell lung cancer, and sales of the blockbuster NSCLC therapy.
Akero Shows FGF21/GLP-1 Combo’s Potential In NASH And Type 2 Diabetes
Phase IIb data show that Akero’s efruxifermin on top of GLP-1 therapy is relatively safe and offers liver fat reductions and fibrosis improvements in NASH patients with type 2 diabetes.